Latest period
$633.30M
YoY change
-3.0%
5Y CAGR
+15.2%
Peak year (2024)
$645.60M
Latest annual
$626.00M
Stock-Based Compensation history chart for Eli Lilly (LLY) from 1989 to 2025
Latest: $626.00M
Stock-Based Compensation growth chart for Eli Lilly (LLY) from 1989 to 2025
Latest: -3.0%
Stock-Based Compensation history table for Eli Lilly (LLY) from 1989 to 2025
| 2025 | $626.00M | -3.0% | −$19.60M | ||
| 2024 | $645.60M | +2.7% | +$17.10M | ||
| 2023 | $628.50M | +69.4% | +$257.40M | ||
| 2022 | $371.10M | +8.3% | +$28.30M | ||
| 2021 | $342.80M | +11.3% | +$34.70M | ||
| 2020 | $308.10M | -1.4% | −$4.30M | ||
| 2019 | $312.40M | +11.8% | +$32.90M | ||
| 2018 | $279.50M | -0.6% | −$1.80M | ||
| 2017 | $281.30M | +10.2% | +$26.00M | ||
| 2016 | $255.30M | +17.2% | +$37.50M | ||
| 2015 | $217.80M | +39.6% | +$61.80M | ||
| 2014 | $156.00M | +7.7% | +$11.10M | ||
| 2013 | $144.90M | +2.4% | +$3.40M | ||
| 2012 | $141.50M | -4.0% | −$5.90M | ||
| 2011 | $147.40M | -36.2% | −$83.60M | ||
| 2010 | $231.00M | -37.3% | −$137.50M | ||
| 2009 | $368.50M | +44.3% | +$113.20M | ||
| 2008 | $255.30M | — | +$255.30M | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | $0.00 | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | $0.00 | ||
| 1999 | $0.00 | — | $0.00 | ||
| 1998 | $0.00 | — | $0.00 | ||
| 1997 | $0.00 | — | $0.00 | ||
| 1996 | $0.00 | — | $0.00 | ||
| 1995 | $0.00 | — | $0.00 | ||
| 1994 | $0.00 | — | $0.00 | ||
| 1993 | $0.00 | — | $0.00 | ||
| 1992 | $0.00 | — | $0.00 | ||
| 1991 | $0.00 | — | $0.00 | ||
| 1990 | $0.00 | — | $0.00 | ||
| 1989 | $0.00 | — | — |
- 2025$626.00M-3.0%
- 2024$645.60M+2.7%
- 2023$628.50M+69.4%
- 2022$371.10M+8.3%
- 2021$342.80M+11.3%
- 2020$308.10M-1.4%
- 2019$312.40M+11.8%
- 2018$279.50M-0.6%
- 2017$281.30M+10.2%
- 2016$255.30M+17.2%
- 2015$217.80M+39.6%
- 2014$156.00M+7.7%
- 2013$144.90M+2.4%
- 2012$141.50M-4.0%
- 2011$147.40M-36.2%
- 2010$231.00M-37.3%
- 2009$368.50M+44.3%
- 2008$255.30M—
- 2007$0.00—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
- 2001$0.00—
- 2000$0.00—
- 1999$0.00—
- 1998$0.00—
- 1997$0.00—
- 1996$0.00—
- 1995$0.00—
- 1994$0.00—
- 1993$0.00—
- 1992$0.00—
- 1991$0.00—
- 1990$0.00—
- 1989$0.00—
Stock-Based Compensation values are taken from Eli Lilly's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Eli Lilly (LLY)
Stock-Based Compensation for Eli Lilly (LLY): headline value $633.30M · YoY -3.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Eli Lilly (LLY) reported stock-based compensation of $626.00M – edged down 3.0% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Eli Lilly stock-based compensation compounded at +15.2% per year, with mixed annual results across the window.
The record annual stock-based compensation stands at $645.60M, reached in 2024; the historical low of $0.00 was recorded in 1989.
Eli Lilly Stock-Based Compensation by Year
Eli Lilly Stock-Based Compensation 2025: $626.00M
Eli Lilly posted stock-based compensation of $626.00M in 2025, edged down 3.0% below 2024.
Eli Lilly Stock-Based Compensation 2024: $645.60M
In 2024, Eli Lilly reported stock-based compensation of $645.60M, edged up 2.7% from 2023. This figure represents the highest annual value in the available history.
Eli Lilly Stock-Based Compensation 2023: $628.50M
Eli Lilly stock-based compensation in 2023 was $628.50M, surged 69.4% from 2022.
Eli Lilly Stock-Based Compensation 2022: $371.10M
2022's stock-based compensation for Eli Lilly came in at $371.10M, grew 8.3% from 2021.
Eli Lilly Stock-Based Compensation 2021: $342.80M
Eli Lilly stock-based compensation in 2021 was $342.80M.
See more financial history for Eli Lilly (LLY).
Sector peers by Stock-Based Compensation
Healthcare peers of Eli Lilly (LLY), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $310.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $310.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation